Evidence map›Paper›PMID 41675222›Full record

ReviewInternational journal of pharmaceutics: X2026

Bioinspired and stimuli-responsive nanocomposites for targeted therapy in ovarian and endometrial tumors.

Jihang Yao, Lulu Liu, Xiufei Teng, Daming Chu, Silu Ding, Hui Li, Hua Chang, Jing Liu

Abstract readReview
In one paragraph

Review in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jihang YaoDepartment Gynecology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Lulu LiuDepartment of Anesthesiology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Xiufei TengDepartment of Anesthesiology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Daming ChuDepartment of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Silu DingDepartment of Radiation Oncology, The First Hospital of China Medical University, Shenyang, China.
Hui LiDepartment Gynecology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Hua ChangDepartment Gynecology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Jing LiuDepartment of Obstetrics, The First Hospital of China Medical University, Shenyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian and endometrial cancers pose significant therapeutic challenges due to late-stage diagnosis and resistance to traditional therapies. Recent progress in the development of multiscale, bioinspired, and stimuli-responsive nanocomposites presents promising avenues for targeted therapy. These nanocomposites, engineered across a range from micrometers to nanometers, utilize hierarchical structures to enhance drug delivery, reduce systemic toxicity, and improve therapeutic efficacy. Through the integration of nanoparticles, hydrogels, and polymeric nanocarriers, these materials can react to external stimuli such as pH, temperature, and magnetic fields, enabling precise and controlled release of therapeutic agents. This review examines the design principles of these sophisticated composites, concentrating on their capacity to replicate the tumor microenvironment and enhance targeting specificity in ovarian and endometrial cancers. Furthermore, it highlights current clinical obstacles, safety considerations, and the considerable potential of these materials in personalized gynecologic oncology, underscoring their efficacy at both macroscopic and nanoscopic levels.

Indexed as

Endometrial tumorsOvarian cancerStimuli-responsive nanocompositesTargeted drug deliveryTumor microenvironment

Identifiers

PMID41675222
PMCPMC12886076

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.